Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02785770 · ClinicalTrials.gov registry record · Phase 1

A Study To Evaluate The Effect Of PF-04447943 On Qtc Interval In Healthy Adult Subjects

A Phase 1 study of Healthy, sponsored by Pfizer.

Completed
Registry status
Phase 1
Development phase
44
Enrollment target
1
Study location

NCT02785770 is a Phase 1 study of Healthy that has completed, run by Pfizer. The registered enrollment target is 44 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02785770, a Phase 1 study of Healthy, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
44 participants
Enrollment target
1
Study location

Study Summary

This is a study designed to ascertain the effect of PF-04447943 on QT interval in healthy adult subjects. This is conducted as part of standard drug development.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Moxifloxacin
  • DRUG PF-04447943

Study Locations (1)

Connecticut

  • Pfizer New Haven Clinical Research Unit - New Haven

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2016-06-29
Est. Completion 2016-10-20
Phase Phase 1

Sponsor

Pfizer

1,845 total trials

What the Registry Record Tells You About NCT02785770

The ClinicalTrials.gov registry entry for NCT02785770 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (93% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT02785770 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT02785770 about?

NCT02785770 is a clinical study titled "A Study To Evaluate The Effect Of PF-04447943 On Qtc Interval In Healthy Adult Subjects". This is a study designed to ascertain the effect of PF-04447943 on QT interval in healthy adult subjects. This is conducted as part of standard drug development.

What is the current status of trial NCT02785770?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2016-06-29. Estimated completion is 2016-10-20.

What conditions does trial NCT02785770 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT02785770?

The interventions under investigation include: Placebo (DRUG), Moxifloxacin (DRUG), PF-04447943 (DRUG).

Who is sponsoring clinical trial NCT02785770?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02785770 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.